Could Virexx Medicals ‘Linked Recognition’ Research Lead To A Cancer

| Total Words: 1078

Could Virexx Medicals ‘Linked Recognition’ Research Lead To A Cancer Vaccine?

A SCIENTIST’S 20-YEAR UNFINISHED JOURNEY TO TREAT HBV MAY OPEN THE DOOR TO A NEW CLASS OF FLEXIBLE VACCINES

While preparing a lecture in biochemistry and virology for his graduate students at the University of Alberta in the early 1980s, Dr. Lorne Tyrrell ran across a study just published in the medical journal, Cell. The research by William Mason and Jesse Summers, entitled Replication of Hepatitis B, discussed their study of the hepatitis B virus in infected duck liver.

After studying their duck model theory, Tyrrell speculated if the hepatitis B virus (HBV) might be susceptible to antiviral agents, and consulted with a colleague, who specialized in nucleoside chemistry. Both medical professors became excited about the possibility of inhibiting the HBV virus with nucleoside analogues. Thus began the infectious disease specialists first leg of a journey, which led to the use of lamivudine as a therapy for chronic HBV infections.

More than 350 million people across the world, especially in Asia, now had new hope, some for their lifelong infections...

To view and download this full PLR article, you must be logged in. Registration is completely free. Once you create your account, you will be able to browse, search & downlod from our PLR articles database of over "1,57,897+" on 1,000's of niches and 200+ categories without paying a penny. Click here to signup...

** PLR to VIDEO: Create Awesome Videos From PLR Articles... FAST!...